The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Hold rating on Johnson & Johnson (JNJ – Research Report), with ...
The healthcare industry continues to evolve. Advancements in science and patients’ increasingly complex needs fuel this ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
“As the ownership group, our philosophy and feelings are that you guys own this team,” Kaufmann said. “It’s our job to make ...
Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...
It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat. J&J holds a leadership role in diverse healthcare ...
Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
WASHINGTON – House Republicans gave Mike Johnson the speaker's gavel on Friday – along with a warning. Nine GOP lawmakers at first either abstained from voting for Johnson or voted for a ...
Ralph Norman and Keith Self, switched their votes for Johnson. (The president-elect called them between ballots, but according to Politico they denied that was the reason for their reversals.